Directory of Peptide API Manufacturing Plants

Wuhan Hualong Biopharmaceutical Co., Ltd., formerly known as Wuhan Meishan Biochemical Pharmaceutical Factory established in 1985, was restructured into the current company in 2000. It is a high-tech pharmaceutical enterprise integrating R&D, production and sales. It has more than 300 employees (more than 200 professional and technical personnel at colleges and above, and 36 practicing pharmacists). The company focuses on the field of injection drugs, especially bio-peptide products, and is one of the top three biochemical pharmaceutical companies in the country. The annual production capacity is about 90 million units. In 2004, it passed the GMP certification as a whole. In 2020, it was certified as a "high-tech enterprise" and won the bid for centralized procurement of national drugs in 2023. The core products of polypeptides include terlipressin injection, thymosin/thymosin injection for injection, somatostatin for injection, bone peptide injection, transfer factor injection, etc., covering cardiovascular and cerebrovascular, immune, digestive and other systemic therapeutic drugs.

Teide Pharmaceutical (Zhejiang) Co., Ltd. (stock code 03880.HK) is a contract research, development and production organization (CRDMO) specializing in polypeptides, providing full-cycle services from early discovery, pre-clinical, clinical development to commercial production. Headquartered in Hangzhou, China, it has commercial production bases and offices in China and the United States, and has been deeply engaged in the field of polypeptides for more than 20 years. Provides CRO (polypeptide new chemical molecular entity discovery synthesis) and CDMO (polypeptide CMC development and commercial production) services, and has extended to oligonucleotide CDMO since 2021. It has provided more than 1,000 customers worldwide with support for the synthesis, development, production and CMC declaration of polypeptides that meet the regulatory requirements of major markets around the world. The project covers more than 50 countries such as China, the United States, Japan, Europe, South Korea and Australia. Clients include large pharmaceutical companies, biotech companies, virtual pharmaceuticals and start-ups. The peptide biochemical tirpopeptide drug substance in the subsidiary has completed the US FDA DMF registration.